XS
TEVA icon

XR Securities’s Teva Pharmaceuticals TEVA Stock Holding History

XR Securities’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,800
Closed -$152K – 333
2024
Q1 		$152K Buy
+10,800
New +$136K ﹤0.01% 322
2021
Q4 		– Sell
-25,800
Closed -$5K – 532
2021
Q3 		$5K Buy
25,800
+2,700
+12% +$25.3K ﹤0.01% 386
2021
Q2 		$5K Sell
23,100
-1,300
-5% -$13.8K ﹤0.01% 409
2021
Q1 		$21K Buy
24,400
+9,100
+59% +$104K ﹤0.01% 405
2020
Q4 		$3K Buy
15,300
+2,500
+20% +$23.9K ﹤0.01% 417
2020
Q3 		$4K Buy
+12,800
New +$135K ﹤0.01% 269
2020
Q1 		– Sell
-44,400
Closed -$5K – 295
2019
Q4 		$5K Buy
44,400
+6,100
+16% +$54.5K ﹤0.01% 216
2019
Q3 		$6K Buy
38,300
+19,000
+98% +$146K ﹤0.01% 214
2019
Q2 		$6K Buy
+19,300
New +$233K ﹤0.01% 241
2019
Q1 		– Sell
-49,700
Closed -$8K – 407
2018
Q4 		$8K Sell
49,700
-24,200
-33% -$496K ﹤0.01% 284
2018
Q3 		$68K Buy
+73,900
New +$1.72M 0.02% 227

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XR Securities's TEVA Position: Q3 2021 in Review

XR Securities sold out of Teva Pharmaceuticals (TEVA) in Q3 2021, closing a stake of 16,860 shares — an estimated $158K sold.

XR Securities first reported a position in TEVA in Q3 2019 and held it in 4 quarters. The position peaked at $231K in Q1 2021. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.

  • XR Securities reported no remaining Teva Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • XR Securities sold 16,860 Teva Pharmaceuticals shares in Q3 2021, an estimated $158K.
  • XR Securities first reported a position in Teva Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • XR Securities's Teva Pharmaceuticals position peaked at $231K in Q1 2021.
  • 429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.

Based on XR Securities's 13F filing for Q3 2021, filed 14 Oct 2021.